-
1.发明授权Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material 有权涉及聚合物，溶剂和高粘度液体载体材料的组合物和方法公开(公告)号：US09572812B2
公开(公告)日：2017-02-21
申请号：US14995658
申请日：2016-01-14
申请人： DURECT CORPORATION , ZOGENIX INC.
发明人： Jeremy C. Wright , Wilma Tamraz , John J. Leonard , John W. Gibson , Keith E. Branham , Stefania Sjobeck , Brooks Boyd , Christopher M. Rubino
IPC分类号： A61K9/19 , A61M5/30 , A61K31/519 , A61K9/00 , A61K47/22 , A61K47/26 , A61K47/34 , A61K9/10 , A61K9/16 , A61K47/10 , A61K47/14 , A61K47/20 , A61K47/44 , A61K9/14 , A61M5/20 , A61M5/31
CPC分类号： A61K31/519 , A61K9/0019 , A61K9/08 , A61K9/10 , A61K9/14 , A61K9/1623 , A61K9/1647 , A61K9/19 , A61K41/0019 , A61K47/10 , A61K47/14 , A61K47/20 , A61K47/22 , A61K47/26 , A61K47/34 , A61K47/44 , A61M5/30 , A61M2005/2013 , A61M2005/2073 , A61M2005/312 , C08G63/08 , C08G63/912
摘要： Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed.
摘要翻译： 组合物可以包括药物活性剂，高粘度液体载体材料（HVLCM），乳酸基聚合物和有机溶剂。 还公开了相关的组合物和方法。
-
公开(公告)号：US09737605B2
公开(公告)日：2017-08-22
申请号：US14773642
申请日：2014-03-11
申请人： DURECT CORPORATION , ZOGENIX, INC.
发明人： Jeremy C. Wright , Wilma Tamraz , John J. Leonard , John W. Gibson , Keith E. Branham , Stefania Sjobeck , Brooks Boyd , Christopher M. Rubino
IPC分类号： A61K47/22 , A61K9/00 , A61K31/519 , A61K47/20 , A61K47/26 , A61M5/20 , A61M5/24 , A61M5/30 , A61M5/315
CPC分类号： A61K47/22 , A61K9/0019 , A61K9/0021 , A61K31/519 , A61K47/20 , A61K47/26 , A61M5/2033 , A61M5/2046 , A61M5/2053 , A61M5/24 , A61M5/30 , A61M5/315 , A61M2205/8206
摘要： Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.
-
公开(公告)号：US10028957B2
公开(公告)日：2018-07-24
申请号：US13790902
申请日：2013-03-08
申请人： DURECT CORPORATION
CPC分类号： A61K31/519 , A61K9/0019 , A61K9/0024 , A61K9/08 , A61K9/10 , A61K47/22 , A61K47/26 , A61K47/34
摘要： Disclosed are formulations and related methods that comprise a non-polymeric, non-water soluble high viscosity liquid carrier material having a viscosity of at least 5,000 cP at 37° C. that does not crystallize neat under ambient or physiological conditions; a specified linear polymer comprising lactide repeat units; and one or more solvents that have a solvent capacity.
-
4.发明授权公开(公告)号：US10226532B2
公开(公告)日：2019-03-12
申请号：US15652655
申请日：2017-07-18
申请人： DURECT CORPORATION
发明人： Jeremy C. Wright , Wilma Tamraz , John J. Leonard , John W. Gibson , Keith E. Branham , Stefania Sjobeck , Brooks Boyd , Christopher M. Rubino
IPC分类号： A61K9/00 , A61M5/20 , A61M5/24 , A61M5/30 , A61K47/20 , A61K47/22 , A61K47/26 , A61M5/315 , A61K31/519
摘要： Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.
-
5.发明授权公开(公告)号：US11285217B2
公开(公告)日：2022-03-29
申请号：US16889115
申请日：2020-06-01
申请人： DURECT CORPORATION
发明人： Jeremy C. Wright , Wilma Tamraz , John J. Leonard , John W. Gibson , Keith E. Branham , Stefania Sjobeck , Brooks Boyd , Christopher M. Rubino
IPC分类号： A61K47/22 , A61K9/00 , A61K31/519 , A61K47/20 , A61K47/26 , A61M5/20 , A61M5/24 , A61M5/30 , A61M5/315
摘要： Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.
-
-
-
-
搜索结果
5 条记录 (耗时 0.022 秒)
